Abstract
Cisplatin-based chemotherapy frequently resulted in acquired resistance of cancer cells. The underlying mechanism of such resistance is not fully understood especially the involvement of autophagy and autophagic cell death. This study thus investigated whether an alteration in autophagy could be responsible for cisplatin resistance in the long-term exposure lung carcinoma cells. The cisplatin resistant clone (H460/cis) of H460 cells was established by exposing the cells with gradually increasing concentrations of cisplatin until chemoresistance acquisition was elucidated by MTT, Hoechst 33342 staining and comet assays. Degree of autophagosome formation and level of LC3 marker were evaluated by acridine orange and western blot analysis, respectively. H460/cis cells exhibited irregular shape with ~3-fold resistant to cisplatin-induced apoptosis compared with H460 cells. Proteins analysis for LC3 indicated that the levels of LC3 in resistant cells were significantly lower than those in H460 cells. Moreover, autophagosome formation detected by acridine orange staining was dramatically reduced in the resistant cells, suggesting the role of autophagy in attenuating of cisplatin-induced cell death. Further, co-treatment of cisplatin with autophagy inducer, trifluorperazine, could resensitize H460/cis cells to cisplatin-induced cell death. Our findings reveal the novel mechanisms causing cisplatin resistance in lung carcinoma cells after long-term drug exposure regarding autophagy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The widely prescribed cisplatin-based chemotherapy has been accepted to be one of the most effective therapeutic approaches for the treatment of many solid tumors; however, acquired drug resistance developed during the therapy has become important obstacle and reduced the survival rate of patients. Based on the concept that the better understanding in molecular basis of such resistance, the more specific and effective strategy could be obtained, researches investigating about the molecular alteration in resistant cancer cells have garnered increasing attention recently.
Likewise, the cellular self-eating machinery termed “autophagy” is in the great interest, and was reported to be associated with several cellular processes including cell death and detoxification. Role of autophagy in affecting cancer cell, live and death, is still in controversial [1–3]. There were some data supporting that autophagy induction could gain benefit for cancer treatment. For example, resveratrol could induce autophagy and resulted in tumor growth arrest in ovarian cancer [4], as well as the treatment of tamoxifen, which targets the estrogen receptor, also induced autophagic cell death in breast cancer cells [5]. However, there was a conflicting evidence indicating that autophagy could promote tumor cell survival and restrict necrosis, inflammation, and could induce tumorigenesis in mouse kidney epithelial (iBMK) cells [6]. Somehow, autophagy also acts as a cytoprotective mechanism protecting DNA damaging effects of Temozolomide and Etoposide in several malignant glioma cell lines [7]. Thus, autophagic process affects differently depending on cell types and particular agents.
Long-term chemotherapeutic exposure is required for the effective cancer therapy. Cisplatin exposure has been long known to result in cisplatin resistance in many cancers. Although it is known that the chemotherapeutic resistance results from the blockage of apoptotic process, utilizing of alternative cell-death pathways in cancer treatment becomes the point of interest. Autophagy can cause cell death in subsequence of strong detrimental stimuli. Besides, the mechanism in regulation of cisplatin resistance regarding autophagy is still far from clear. This study thus investigated the molecular alteration of autophagy in that resistant H460/cis cells generated by long-term cisplatin exposure. We demonstrated herein for the first time that the cell exposure to cisplatin could adapt cell death machinery toward inhibition of autophagy and consequently reduced their sensitivity to cisplatin-induced apoptosis. As microtubule-associated protein 1 light chain 3 (MAP1LC3) or LC3 is recognized as the marker of autophagy, we also found that the ratio of LC3 type II to I also decreased in H460/cis cells. Moreover, addition of an autophagic inducer trifluorperazine (TFP) to cisplatin-treated H460/cis cells could sensitize the cells to cisplatin-mediated death. Thus, our results revealed that such adaptation during cisplatin exposure was regard to autophagy downregulation, which these findings should facilitate the strategy in resistant cancer treatment.
Materials and methods
Cell culture and reagents
Human non-small cell lung cancer cells H460 (NCI-H460) cells were obtained from the American Type Culture Collection (Manassas, VA, USA) was cultured in RPMI 1640 containing 10% fetal bovine (Hyclone, Cramlington, UK), 1% penicillin and streptomycin (Gibco, Carlsbad, CA, USA) in a humid atmosphere of 5% CO2 at 37°C. H460 cells were grown, and cisplatin (Sigma, St. Louis, MO, USA) was then added to the medium at gradually increasing concentrations starting from 0.33 μM (0.1 μg/ml) until the concentration reached 4.67 μM (1.4 μg/ml). During continuous exposure to cisplatin, culture medium was replaced with freshly prepared medium containing cisplatin at indicated concentrations every 3 days and maintained in that concentration for at least two passages [8, 9]. Cell population survived when concentration reach 4.67 μM was named H460/cis cells.
Determination of cisplatin cytotoxicity
H460 cells and H460/cis cells were harvested with trypsin and resuspended in a final concentration of 1 × 105 cells/ml. 200 μl of cell suspension was distributed evenly into 96-well cell culture plate. After 24 h of incubation, various concentrations of cisplatin were added to cells and further incubated for 24 h. After incubation period, cell viability is determined by MTT assay [10, 11]. In brief, 100 μl of 0.4 mg/ml MTT (Sigma, St. Louis, MO, USA) was added into each well and further incubated for 4 h. Formazan crystals were dissolved in 100 μl DMSO. The absorbance of formazan solution is quantified by Microplate reader at 570 nm. Concentration of cisplatin at IC50 was calculated by CurveExpert 1.3.
For apoptosis detection
Cells were stained with 10 μM Hoechst 33342 (Sigma, St. Louis, MO, USA), and the fluorescent dye stained in cells was visualized by a fluorescence microscope. Cells that displayed intensely condensed and/or fragment nuclei stained by Hoechst 33342 were considered as apoptotic cells.
Comet single cell gel electrophoresis systems
Cells were trypsinized and suspended in 1% low melting agarose. Then, they were spread on a microscope slide precoated with 0.8% of normal melting agarose. After letting the low melting agarose dry, slides were placed in a lysis solution (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris-base pH 10, 1% Triton X-100, and 10% DMSO) for 60 min at 4°C (protected from light). Then, slides were equilibrated in electrophoresis buffer (0.3 M NaOH, 1 mM EDTA, pH > 13), and were run in a horizontal electrophoresis chamber at 700 mA 25 V for 5 min. Slides were washed with Tris buffer pH 7.5 and fixed with absolute MeOH for 5 min [12, 13]. Finally, slides were stained with SYBRgreen. The pictures of unwind DNA taken under inverted fluorescence microscope were analyzed by CometScore v1.5 for tail length, %DNA in tail, tail moment, and olive moment parameters. More than 70% in each parameter, compared with untreated control, was considered as the cut-off point of toxicity and apoptosis cell death.
Qualitative and quantitative analysis of autophagosome formation
Cells were harvested, centrifuged at 1,200 rpm for 5 min, washed with PBS twice, resuspended in 1 μM acridine orange (AO, Sigma, St. Louis, MO, USA), and incubated for 17 min [14, 15]. Autophagosome formation was qualitatively detected by fluorescence inverted-microscope (IX51 Olympus, Japan). Moreover, AO fluorescence intensity was also measured by flow cytometry (BD FACSCalibur, CA, USA).
Western blotting
Cells were harvested with trypsinization, and then washed twice with PBS. Cells were incubated with ice-cold lysis buffer (50 mM Tris pH 7.4, 100 mM NaCl, 2 mM EDTA, 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 2 mM Na3VO4 and complete mini-cocktail protease inhibitors) for 30 min at 4°C. After centrifugation at 15,000 rpm for 15 min, supernatants were collected [16]. Samples containing 30 μg of proteins were denatured, loaded, and separated on 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Protein bands were transferred to PVDF membranes, and blocked for 1 h at room temperature with 5% skim milk in TBST (10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 0.01% tween20). The membranes were immunoblotted with rabbit polyclonal LC3 antibody (1:500, Abcam: Cambridge, MA, USA). To assure equivalent protein loaded, the membranes are simultaneously incubated with mouse monoclonal β-actin antibody (1:3,000, Abcam: Cambridge, MA, USA). Membranes were washed three times with TBST, incubated with HRP-conjugated rabbit IgG secondary antibody (1:3,000, Abcam: Cambridge, MA, USA) for 1 h at room temperature and washed extensively before detection. Protein bands were visualized using an enhanced chemiluminescence Western blot analysis system (Pierce, Rockford, IL, USA), and quantified the protein bands using ImageJ 1.43u software (NIH, USA).
Statistical analysis
All results from three or more independent experiments were expressed in mean ± SEM. Statistical differences between means were determined using analysis of variance (ANOVA) and post hoc test. P < 0.05 was selected to reflect significance.
Results
Exposure to gradually increasing concentrations of cisplatin rendered H460 cells resist to cisplatin-mediated death
Cisplatin exposure during chemotherapy is likely to force cancer cell adaptation for acquired drug resistance. Cisplatin resistant clone of lung carcinoma H460 cells was generated by continuous exposure to stepwise increasing concentrations of cisplatin starting from 0.33 μM until reaching 4.67 μM over a period of 12 months. After establishment of H460/cis cells, we characterized cell death in response to cisplatin treatment (0.1–1,000 μM) in these cells comparing with those parental H460 cells. Cell viability assay revealed that percentage of cell survival of H460 and H460/cis cells decreased in dose-dependent manner. At 100 μM of cisplatin, the percentage of cell viability in both cells showed significantly difference (Fig. 1a). H460/cis cells exhibited ~2.4 times more resistant than H460 cells (P < 0.001) with the 50% inhibitory concentrations (IC50) of cisplatin in H460 and H460/cis were 37.6 ± 0.7 μM and 90.7 ± 4.4 μM, respectively (Fig. 1b). It was noteworthy noting that under phase-contrast microscopy, H460 cells had an irregular shape and enlargement in size of the cells comparing to the parental H460 cells (Fig. 1c). Further, we evaluated mode of cell death in response to cisplatin. Both cisplatin resistant and sensitive cells were treated with cisplatin at the concentration of 40 μM, and Hoechst 33342 and propidium iodide (PI) staining were accessed. After 24 h of cisplatin treatment, H460 cells underwent apoptotic cell death ~20% as determined by the increase in number of cells with intense blue fluorescence and chromatin condensation (Fig. 2a, b). Meanwhile, only 7% apoptosis could be detected in H460/cis cells (Fig. 2a, b). PI staining assay provided the information that less necrotic cells could be observed in both H460 and H460/cis cells (Data not shown). Further, our results obtained from comet assay indicated that, H460/cis had fewer apoptosis characteristics than those of H460 cells (Fig. 3a, b).
Cisplatin exposure suppressed autophagosome formation in lung cancer cells
Autophagy has garnered increasing attention recently since autophagy plays a key role in either cellular detoxify mechanism or cell death determination [5]. We thus tested whether the reduction of cell viability in response to cisplatin in H460/cis cells involved autophagy. Since autophagy associated with cellular machinery in autophagosome formation, AO dye, a specific autophagosome indicator [14, 15, 17] was used. H460 and H460/cis cells were stained with 1 μM of AO for 17 min, and autophagosome was visualized under fluorescence inverted microscope. As shown in Fig. 4a, H460/cis cells exhibited lower in both AO intensity and a number of intracellular AO-positive spots, than those of H460 cells. We further quantified the presence of autophagosome by subjecting the stained cell to flow cytometer with FACS analysis. The consistent results were obtained and indicated that the degree of autophagy in H460/cis cells were noticeably diminished that in H460 cells (Fig. 4b, c).
To date, the transformation of microtubule-associated protein 1 light chain 3 (MAP1LC3 or LC3) protein from the native cytosolic form of LC3 (LC3-I) to membrane-bound lapidated (LC3-II) is recognized as an important process of autophagosome formation [16, 17]. The proportion of LC3-II conversion is used as an indicator of autophagy activity. We confirmed the decrease of autophagosome formation during the process of H460/cis cells establishment by western blot analysis detecting LC3-I and LC3-II levels. As shown in Fig. 4d, the ratio of LC3-II conversion was dramatically decreased in a time-dependent manner. The degree of autophagy in H460/cis cells was ~47% compared with that of parental H460 cells. Together our results indicated for the first time that the adaptation of lung carcinoma cells in response to cisplatin exposure involved alteration in cellular autophagy level.
Reduction of autophagosome was responsible for cisplatin resistance in H460 cells
Since H460/cis cells exhibited significantly less autophagic activity, we further tested whether such reduction was associated with cisplatin resistance. TFP, a known autophagic inducer, was used to induce autophagosome formation in these cells. H460 and H460/cis cells were co-treated with TFP at the concentration of 5 μM and cisplatin at the concentration of 40 μM, and then cell viability was evaluated by MTT assay. When treatment of cells with TFP alone showed neither toxic nor proliferative effect on these cells (data not shown), the co-treatment of cisplatin and TFP in H460/cis cells exhibited significantly sensitized H460/cis cells to cisplatin-induced cytotoxicity compared with cisplatin-treated control (Fig. 5). On the contrary, the additional TFP in cisplatin treatment had no augmentative effect in H460 cells.
Moreover, we also inhibited autophagic inductive effects of TFP in H460/cis cells with 3-methyladenine (3-MA), the specific phosphatidylinositol-3 kinase (PI3K) class III which regulated autophagic activity [17]. The introduction of 3-MA at the concentration of 200 μM could reverse sensitizing effect of autophagic inducer and cell viability in response to the treatment was increased to approximately the same level of that in cisplatin-treated alone as shown in Fig. 5. These suggested that the acquired resistance of H460/cis cells resulting from long-term exposure to cisplatin at least partly involved the machinery of cell in suppression of autophagy.
Discussions
Acquired resistance to chemotherapy is a major hindrance to the success of cancer treatment. Understanding the underlying mechanisms by which tumors become resistant to a particular agent is key to identifying new drugs or combination regimens. For cisplatin, an effective agent, using worldwide for the treatment of various cancers, including lung cancer. For the best treatment outcome, it has to be administrated repetitively. However, its therapeutic efficacy is limited due to the initiation of acquired resistance. The mechanisms of cisplatin resistance appear to be multifactorial and believed to process through 4 main pathways which are a change of drug transportation, an increase of drug detoxifying systems, a modification in DNA repairing machinery, and alteration in the apoptotic cell death pathways [18–21].
The term of “autophagy” becomes a great interest in cancer research field nowadays. In order to comprehend the involvement of autophagy on cisplatin resistance in non-small cell lung carcinoma, we established the resistant non-small cell lung carcinoma H460 cells by exposing the cells with continuous administration of cisplatin. As the results of cell viability assay, H460/cis cells could not undergo cell death in cisplatin treatment at IC50 concentration. This means that apoptotic cell death pathway or type I programmed cell death was blocked in these cells (Figs. 1, 2, 3). Autophagy is the process of cell components degradation itself through the machinery of lysosome, which turns to be the cause of cell death [22–24]. However, in certain conditions autophagy resulted in an increasing survival of cells in response to death stimuli and the different outcomes are likely to depend on cell types, agents used, and condition of treatment [1–7]. The protective role of autophagy was presented in several previous studies. When autophagy was induced by death stimuli, its function was most likely trended to facilitate cell survival. On the contrary, we found that treatment of the cells with barely toxic dose of cisplatin for relatively long time could result in a decrease of autophagy that plays an opposite role on cell survival. Importantly, such reductions of autophagy in H460/cis cells detected by AO-cell staining and western blot analysis of LC3 (Fig. 4d) was concomitant with the decrease response to cisplatin-mediated cells death implying that the autophagy could be responsible for cisplatin-induced resistance in these cells.
Previous reports have indicated that long-term cisplatin treatment also resulted in Bcl-2 overexpression [9, 25–29]. Moreover, Bcl-2 protein has been shown to act as a negative inhibitor of autophagy [27–32] via its interaction with Beclin 1 [33]. Consistent with above mentions, our results showed that H460/cis cells exhibited higher level of Bcl-2 than that of parental H460 cells (data not shown) with reduced autophagy. Taken together, not only did the present study indicate for the first time that long-term exposure of lung carcinoma cells to cisplatin resulted in autophagic reduction, but also supported the previous observation that Bcl-2 protein acted as a negative regulator for autophagy as well as apoptosis. Furthermore, we found that addition of autophagic inducer TFP to H460/cis cells could reverse the resistance of the cells to cisplatin-mediated apoptosis (Fig. 5). Co-treatment of cisplatin and TFP could reduce percentage of H460/cis cell viability back to the level of parental H460 cells. This finding has strengthened the possibility that long-term cisplatin exposure renders cells resisting to the drug via autophagy-dependent mechanism.
In summary, the present study reported herein that long-term exposure to cisplatin led to cisplatin resistance in lung carcinoma H460 cells and lowered autophagy level. These observations inferred that long-term exposure to cisplatin caused acquired drug resistance through the mechanism involving autophagy reduction. Therefore, upregulation of autophagy may be a useful adjuvant approach for treatment cancer to prevent resistance in further therapy.
References
Edinger AL, Thompson CB (2003) Defective autophagy leads to cancer. Cancer Cell 4:422–424
Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891–2906
Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463–477
Opipari AW, Tan L, Boitano AE, Sorenson AR, Aurora A, Liu JR (2004) Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 64:696–703
Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51–64
Katayama M, Kawaguchi T, Berger MS, Pieper RO (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14:548–558
Mese H, Sasaki A, Alcalde RE, Nakayama S, Matsumura T (1998) Establishment and characterization of cisplatin-resistant human epidermoid carcinoma cell line, A431 cell. Chemotherapy 44:414–420
Yoon SS, Ahn KS, Kim SH, Shim YM, Kim J (2001) In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype. Lung Cancer 33:221–228
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Singh NP, McCoy MT, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–191
Olive PL, Durand RE, Banáth JP, Johnston PJ (2001) Analysis of DNA damage in individual cells. Methods Cell Biol 64:235–249
Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I (2003) Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63:2103–2108
Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D, Yahalom J (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61:439–444
Egami Y, Kiryu-Seo S, Yoshimori T, Kiyama H (2005) Induced expressions of Rab24 GTPase and LC3 in nerve-injured motor neurons. Biochem Biophys Res Commun 337:1206–1213
Mizushima N, Yoshimori T, Levine B (2010) Methods in mammalian autophagy research. Cell 140:313–326
Köberle B, Tomicic MT, Usanova S, Kaina B (2010) Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806:172–182
Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279
Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9–23
Wang CW, Klionsky DJ (2003) The molecular mechanism of autophagy. Mol Med 9:65–76
Inoue K, Kuwana H, Shimamura Y, Ogata K, Taniguchi Y, Kagawa T, Horino T, Takao T, Morita T, Sasaki S, Mizushima N, Terada Y (2010) Cisplatin-induced macroautophagy occurs prior to apoptosis in proximal tubules in vivo. Clin Exp Nephrol 14:112–122
Eum KH, Lee M (2011) Crosstalk between autophagy and apoptosis in the regulation of paclitaxel-induced cell death in v-Ha-ras-transformed fibroblasts. Mol Cell Biochem 348:61–68
Sartorius UA, Krammer PH (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584–592
Waggoner SE, Baunoch DA, Anderson SA, Leigh F, Zagaja VG (1998) Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53. Ann Surg Oncol 5:544–547
Muilenburg DJ, Coates JM, Virudachalam S, Bold RJ (2010) Targeting Bcl-2-mediated cell death as a novel therapy in pancreatic cancer. J Surg Res 2:276–281
Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, Jeon JH, Lee ES, Byun SS, Lim HM, Song EY, Lim JS, Yoon DY, Lee HG, Choe YK (2006) Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of bax translocation in human bladder cancer cells. Cancer Lett 237:56–66
Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M (2007) Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 11:2387–2394
Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G, Takaku F (2007) Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 7:1263–1269
Lam D, Levraud JP, Luciani MF, Golstein P (2007) Autophagic or necrotic cell death in the absence of caspase and bcl-2 family members. Biochem Biophys Res Commun 363:536–541
Thorburn A (2008) Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis 13:1–9
Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927–939
Acknowledgments
This research was supported by grant fund under the program Strategic Scholarships for Frontier Research Network for the Join Ph.D. Program Thai Doctoral degree from the Office of the Higher Education Commission, Thailand, and the 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) from Chulalongkorn University, Thailand. Further, the authors are grateful to Mr. Krich Rajprasit, a proofreader.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Sirichanchuen, B., Pengsuparp, T. & Chanvorachote, P. Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells. Mol Cell Biochem 364, 11–18 (2012). https://doi.org/10.1007/s11010-011-1199-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-011-1199-1